Ligand Pharma (LGND) Introduces 2025 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
December 10, 2024 9:00 AM ESTIntroduces 2025 full year revenue guidance of $180 million to $200 million, a 17% increase in revenue growth over 2024, and core adjusted earnings per diluted share of $6.00 to $6.25 Twelve commercial-stage programs and late-stage pipeline are expected to drive strong revenue growth over the next five years Long-term royalty receipts expected to deliver at least a 22% compound annual growth rate
JUPITER, Fla.--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from... More
